Charles A. Deignan
2018
In 2018, Charles A. Deignan earned a total compensation of $434.4K as Chief Financial Officer at Clearside Biomedical, a 49% decrease compared to previous year.
Compensation breakdown
| Bonus | $7,500 |
|---|---|
| Non-Equity Incentive Plan | $88,096 |
| Salary | $330,065 |
| Other | $8,700 |
| Total | $434,361 |
Deignan received $330.1K in salary, accounting for 76% of the total pay in 2018.
Deignan also received $7.5K in bonus, $88.1K in non-equity incentive plan and $8.7K in other compensation.
Rankings
In 2018, Charles A. Deignan's compensation ranked 12,317th out of 14,244 executives tracked by ExecPay. In other words, Deignan earned more than 13.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,317 out of 14,244 | 14th |
Division Manufacturing | 4,982 out of 5,765 | 14th |
Major group Chemicals And Allied Products | 1,881 out of 2,128 | 12th |
Industry group Drugs | 1,609 out of 1,817 | 11th |
Industry Pharmaceutical Preparations | 1,234 out of 1,391 | 11th |
Source: SEC filing on April 26, 2019.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2018.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019